Why JG Zebra Consulting?
JG Zebra provides international and national level strategic advice and consultancy services to the life sciences industry, patient organisations, and other key stakeholders. We specialise in rare diseases and novel therapies, with a particular focus on market access, public policy and stakeholder engagement.
We prioritise truly understanding our clients’ needs and demystifying market access strategy and public policy, ensuring they have the knowledge and tools to understand and shape the policy and access environment.
JG Zebra works with industry, patient advocates, healthcare professionals and other key stakeholders to support improvements in care for patients with serious conditions, from diagnosis to access to new treatments.
JG Zebra is headed by Josie Godfrey, who has 20 years’ experience in health policy, stakeholder engagement and market access. She set up the NICE Highly Specialised Technologies programme and its predecessor the Advisory Group for National Specialised Services (AGNSS).
Josie is Strategic Director for Project HERCULES, an award winning international multi-stakeholder collaboration developing disease level tools and evidence to support Health Technology Assessment of new treatments for Duchenne Muscular Dystrophy
We partner with other individuals and organisations to bring together the best team to meet our clients’ needs.
What We Do
Market access strategy
Rare disease market access health checks
Strategic evidence plans
Market access strategies and roadmaps
Market access strategy workshops
Preparing for HTA, including mock appraisals
Audit of policy barriers to access
Policy strategy and initiatives
Consultation responses and position statements
Facilitating and chairing multi-stakeholder workshops
Stakeholder engagement plans
Project planning and delivery
Research and writing
Committee secretariat services
Lectures and workshops
JG Zebra has taken a leading role in setting up and running the EURORDIS award-winning Project HERCULES, an ongoing collaboration led by patient organisation Duchenne UK. We provide project management and Josie Godfrey acts as Strategic Director. Bringing together patients and carers, clinicians, industry, academia, HTA bodies and other stakeholders, the project has broken new ground in developing tools to promote access to treatments in rare diseases. Project HERCULES has delivered a gold standard economic model for Duchenne Muscular Dystrophy, and the tools and data required to populate the model.
Find out more at https://hercules.duchenneuk.org
JG Zebra supported the establishment of a Gene and Cell Therapy Working Group for the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE). Bringing together over 12 companies and identifying shared priorities, we developed an agreed position statement and work programme for the group, focussing on shared understanding, challenges and potential solutions to access and the commercialisation of novel therapies, covering topics such as Health Technology Assessment, pricing and reimbursement, cross-border healthcare and hospital exemption.
JG Zebra recently supported a rare disease biotech company to develop a market access strategy for the UK. Working with the client to understand their needs, we identified skills and data gaps in the planned approach to market access, developed a strategic evidence plan and prepared for negotiations with NHS England and for scoping and assessment by NICE.